Article updated and reviewed by Christos Ballas, MD, Attenting Psychiatrist, Inpatient and Consult/Liaison Psychiatry, Hospital of the University of Pennsylvania. Editorial review provided by VeriMed Healthcare Network on May 11, 2005.
Today, the FDA approved Risperdal for the treatment of schizophrenia in adolescents 13 to 17 years old and for the short-term (three week)... Read more »
The approval by the FDA for the use of Risperdal in the treatment of schizophrenia and bipolar disorder in children is a momentous event.... Read more »
This SharePost is the second in a series devoted to schizophrenia treatment and it focuses specifically on some of the atypical drugs used... Read more »
Just because it's newer doesn't mean it's better. This is the message to come from recent studies that have examined the therapeutic... Read more »
Almotriptan, better known as Axert and Almogran, is one of eight triptan medications developed to abort a Migraine attack in... Read more »
Robin Cunningham holds a Bachelors degree in Zoology from the University of Washington. After graduate studies in psychology at Washington and The... Read more »
Source: ADAM Encyclopedia
Depression - adolescents; Teenage depressionSymptomsDepression can change the way teenagers see themselves, their lives, and the people around them.... Read more »
Jan Gambino is a freelance writer and mother of children with acid reflux disease.Jan holds a B.S. degree in Special Education and Elementary... Read more »
This is a study to determine if flexibly-dosed Geodon is a safe and effective treatment for adolescents with schizophrenia. This international study... Read more »
This is a study to evaluate the long-term safety and effectiveness of Invega XR, given in flexible doses, to teens with schizophrenia. This national... Read more »